Anti-CD3 antibody ameliorates experimental autoimmune uveitis by inducing both IL-10 and TGF-β dependent regulatory T cells

Copyright © 2010 Elsevier Inc. All rights reserved.

Détails bibliographiques
Publié dans:Clinical immunology (Orlando, Fla.). - 1999. - 138(2011), 3 vom: 25. März, Seite 311-20
Auteur principal: Ke, Yan (Auteur)
Autres auteurs: Jiang, Guomin, Sun, Deming, Kaplan, Henry J, Shao, Hui
Format: Article en ligne
Langue:English
Publié: 2011
Accès à la collection:Clinical immunology (Orlando, Fla.)
Sujets:Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Antibodies, Monoclonal CD3 Complex IL10 protein, mouse Transforming Growth Factor beta Interleukin-10 130068-27-8
LEADER 01000caa a22002652c 4500
001 NLM205259081
003 DE-627
005 20250714182202.0
007 cr uuu---uuuuu
008 231223s2011 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.clim.2010.12.016  |2 doi 
028 5 2 |a pubmed25n1430.xml 
035 |a (DE-627)NLM205259081 
035 |a (NLM)21256812 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Ke, Yan  |e verfasserin  |4 aut 
245 1 0 |a Anti-CD3 antibody ameliorates experimental autoimmune uveitis by inducing both IL-10 and TGF-β dependent regulatory T cells 
264 1 |c 2011 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 14.04.2011 
500 |a Date Revised 29.05.2025 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
520 |a Copyright © 2010 Elsevier Inc. All rights reserved. 
520 |a Chronic/recurrent autoimmune (idiopathic) uveitis is difficult to treat and they account for approximately 10% of legal blindness in the Western world. As it has been reported that anti-CD3 antibody can enhance T cell regulatory function, we investigated its effects in vivo on experimental autoimmune uveitis (EAU), a model for autoimmune uveitis in humans. B10RIII mice immunized with an uveitogenic peptide were treated with the F(ab')(2) fragment of anti-CD3 mAb either before or at clinical disease onset. Evaluation of EAU and cellular responses showed that disease was inhibited and the activation and expansion of pathogenic T cells selectively reduced, whereas functions of Treg in vivo were enhanced. Moreover, mice treated with anti-CD3 mAb were resistant to a second challenge with antigen and thus protected from recurrence of disease. Our results demonstrate that anti-CD3 mAb is a potent inhibitor of autoimmune uveitis 
650 4 |a Journal Article 
650 4 |a Research Support, N.I.H., Extramural 
650 4 |a Research Support, Non-U.S. Gov't 
650 7 |a Antibodies, Monoclonal  |2 NLM 
650 7 |a CD3 Complex  |2 NLM 
650 7 |a IL10 protein, mouse  |2 NLM 
650 7 |a Transforming Growth Factor beta  |2 NLM 
650 7 |a Interleukin-10  |2 NLM 
650 7 |a 130068-27-8  |2 NLM 
700 1 |a Jiang, Guomin  |e verfasserin  |4 aut 
700 1 |a Sun, Deming  |e verfasserin  |4 aut 
700 1 |a Kaplan, Henry J  |e verfasserin  |4 aut 
700 1 |a Shao, Hui  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Clinical immunology (Orlando, Fla.)  |d 1999  |g 138(2011), 3 vom: 25. März, Seite 311-20  |w (DE-627)NLM098196855  |x 1521-7035  |7 nnas 
773 1 8 |g volume:138  |g year:2011  |g number:3  |g day:25  |g month:03  |g pages:311-20 
856 4 0 |u http://dx.doi.org/10.1016/j.clim.2010.12.016  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_24 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 138  |j 2011  |e 3  |b 25  |c 03  |h 311-20